Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma(NLG2107) | terminated | Phase 2 | 21 | NewLink Genetics CorporationINDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT03259425 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Jun 13, 2022 |
| clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | terminated | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02009384 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | terminated | Phase 2 | 2 | University of LouisvilleOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT00615160 | PTK/ZK in Disseminated Malignant Melanoma | terminated | Phase 1 / Phase 2 | 9 | Michael WeichenthalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02375984 | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas(TIL) | terminated | Phase 2 | 1 | Saint John's Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02974803 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | terminated | Phase 2 | 6 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 241 | Dynavax Technologies CorporationINDUSTRY | 4 | Aug 3, 2021 | clinicaltrials |
| NCT02097732 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | terminated | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03224208 | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients(VECODUE) | terminated | Phase 2 | 9 | Fondazione Melanoma OnlusOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | terminated | Phase 2 | 2 | Elizabeth DavisOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT00961844 | Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma | terminated | Phase 1 / Phase 2 | 15 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02303951 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC(NEO-VC) | terminated | Phase 2 | 47 | University Hospital TuebingenOTHER | 2 | Feb 3, 2021 | clinicaltrials |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | terminated | Phase 2 | 6 | University Hospital TuebingenOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00515528 | Vaccination Plus Ontak in Patients With Metastatic Melanoma | terminated | Phase 2 | 17 | University of ChicagoOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00003509 | Antineoplaston Therapy in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03354962 | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | terminated | Phase 1 / Phase 2 | 6 | Institut Claudius RegaudOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03241927 | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | terminated | Phase 2 | 1 | Nina BhardwajOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02410863 | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma(BOTTOM) | terminated | Phase 2 | 10 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | terminated | Phase 2 | 5 | GlaxoSmithKlineINDUSTRY | 3 | Oct 8, 2020 | clinicaltrials |
| NCT01942993 | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | terminated | Phase 2 | 3 | Philip FriedlanderOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00505635 | Biochemotherapy With Temozolomide for Metastatic Melanoma | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02889861 | IMCgp100-401 Rollover Study | terminated | Phase 2 | 3 | Immunocore LtdINDUSTRY | 2 | Jul 27, 2020 | clinicaltrials |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | terminated | Phase 2 | 1 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | terminated | Phase 1 / Phase 2 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma(Mel62; 6PAC) | terminated | Phase 1 / Phase 2 | 3 | Craig L Slingluff, JrOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02718391 | Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.(ACDC) | terminated | Phase 2 | 12 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 23 | University of WashingtonOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01369875 | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02190838 | Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma | terminated | Phase 2 | 57 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01264081 | Lapatinib in Stage IV Melanoma With ERBB4 Mutations | terminated | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | terminated | Phase 2 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00729807 | 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma | terminated | Phase 2 | 6 | University of Maryland, BaltimoreOTHER | 1 | Aug 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2022source: clinicaltrials